Novel GPR119 agonist HD0471042 attenuated type 2 diabetes mellitus

Emerging combinatorial hormone therapies for the treatment of obesity and T2DM

(2013) Sharon A. Sadry et al.   Nature Reviews Endocrinology

Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus

(2013) Sonal Singh et al.   JAMA Internal Medicine

The therapeutic potential of GPR119 agonists for type 2 diabetes

(2012) Takahide Ohishi et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Novel GPR119 agonist AS1535907 contributes to first-phase insulin secretion in rat perfused pancreas and diabetic db/db mice

(2010) Shigeru Yoshida et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

The role of small molecule GPR119 agonist, AS1535907, in glucose-stimulated insulin secretion and pancreatic β-cell function

(2010) S. Yoshida et al.   DIABETES OBESITY & METABOLISM

N-Oleoyldopamine Enhances Glucose Homeostasis through the Activation of GPR119

(2009) Zhi-Liang Chu et al.   MOLECULAR ENDOCRINOLOGY

A Role for Intestinal Endocrine Cell-Expressed G Protein-Coupled Receptor 119 in Glycemic Control by Enhancing Glucagon-Like Peptide-1 and Glucose-Dependent Insulinotropic Peptide Release

(2008) Zhi-Liang Chu et al.   ENDOCRINOLOGY

Hormone-based therapies in the regulation of fuel metabolism and body weight

(2008) Nicole C Kesty et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Discovery of the First Potent and Orally Efficacious Agonist of the Orphan G-Protein Coupled Receptor 119

(2008) Graeme Semple et al.   JOURNAL OF MEDICINAL CHEMISTRY

Type 2 diabetes: new genes, new understanding

(2008) Inga Prokopenko et al.   TRENDS IN GENETICS